Investigator Site #1
Auckland, New Zealand
Location status: Recruiting
NCT Number: NCT07429006
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with four dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with one dose cohort. Approximately 32 participants in SAD and 12 in MAD are planned to be enrolled.
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Phase 1
Auckland, New Zealand
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
AKB-9090 will be administered intravenously
Matching Placebo administered intravenously
Time frame: From First Dose to Day 7
Time frame: From First Dose to Day 7
Time frame: From First Dose to Day 7
Time frame: From First Dose to Day 7
Time frame: From First Dose to Day 7
Time frame: from first dose to Day 7
Time frame: From First Dose to Day 7
Time frame: From First Dose to Day 7
Time frame: From First Dose to Day 7
Time frame: At Day 1
Time frame: At Day 1
Time frame: At Day 1
Time frame: At Day 1
Time frame: At Day 1
Time frame: At Day 1
Time frame: At Day 1 and Day 7
Time frame: At Day 1 and Day 7
Time frame: At Day 1
Time frame: At Day 1 and Day 7
Time frame: At Day 1 and Day 7
Time frame: At Day 7
Time frame: Baseline (Day 1) and at 6, 12, 18, and 24 hours post-dose
Time frame: Baseline (Day 1) and At Days 2, 8, and 13
Time frame: Baseline (Day 1) and At Days 2, 8, and 13
Time frame: Baseline (Day 1 and Day 7) and at 6, 12, 18, and 24 hours post-dose
Time frame: Baseline (Day 1) and At Days 4, 8, 14, and 21
Time frame: Baseline (Day 1) and At Days 4, 8, 14, and 21
Contact information is provided by the study sponsor or research team.
Akebia Therapeutics
Industry
A Randomized, Double-Blind, Placebo-Controlled, Single (SAD) and Multiple Ascending-Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKB-9090 Administered Intravenously to Healthy Adult Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07674446
Healthy Volunteers
Hyderabad, India
View Trial DetailsNCT02543983
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT07710872
Bacterial Infections, Bacterial Infections and Mycoses
Jingxi, China
View Trial DetailsNCT03538600
Healthy Volunteers
Bethesda, Maryland, United States
View Trial Details